3篇
您的检索式：作者名="Man Hei Cheung"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Transfusion-transmitted hepatitis E:What we know so far?显示文摘Hepatitis E virus(HEV)is a major cause of viral hepatitis globally.There is growing concern about transfusion-transmitted HEV(TT-HEV)as an emerging global health problem.HEV can potentially result in chronic infection in immunocompromised patients,leading to a higher risk of liver cirrhosis and even death.Between 0.0013%and 0.281%of asymptomatic blood donors around the world have HEV viremia,and 0.27%to 60.5%have anti-HEV immunoglobulin G.HEV is infectious even at very low blood concentrations of the virus.Immunosuppressed patients who develop persistent hepatitis E infection should have their immunosuppressant regimen reduced;ribavirin may be considered as treatment.Pegylated interferon can be considered in those who are refractory or intolerant to ribavirin.Sofosbuvir,a nucleotide analog,showed modest antiviral activity in some clinical studies but sustained viral response was not achieved.Therefore,rescue treatment remains an unmet need.The need for HEV screening of all blood donations remains controversial.Universal screening has been adopted in some countries after consideration of risk and resource availability.Various pathogen reduction methods have also been proposed to reduce the risk of TT-HEV.Future studies are needed to define the incidence of transmission through transfusion,their clinical features,outcomes and prognosis. | Carmen Ka Man Cheung Sunny Hei Wong Alvin Wing Hin Law Man Fai Law | 2022 | World Journal of Gastroenterology2022，28，1： | 5 |
| 2 | pPeOp inhibits HGC-27 cell proliferation,migration and invasion by upregulating miR-30b-5p and down-regulating the Rac1/Cdc42 pathway显示文摘Gastric cancer is the fifth most frequently occurring and the fourth most lethal malignant cancer worldwide.A bioactive protein(pPeOp)from Omphalia lapidescens exhibits significant inhibitory effects on gastric cancer cells.miRNA deep sequencing analysis shows that miR-30b-5p is significantly upregulated in HGC-27 cells treated with pPeOp.Verification results show that the expression level of miR-30b-5p is significantly increased in HGC-27 cells after pPeOp treatment.Additionally,miR-30b-5p is significantly downregulated in clinical gastric cancer tissues compared to that in adjacent normal tissues.Following pPeOp treatment and/or transfection with miR-30b-5p mimic,the proliferation,migration,and invasion of HGC-27 cells are significantly impaired.Immunofluorescence microscopy shows that pPeOp and/or miR-30b-5p destroy(s)microfilaments and microstructures and inhibit(s)the formation of pseudopodia.Bioinformatics analysis,dual-luciferase reporter assay,and western blot analysis confirm that miR-30b-5p downregulates Rac1/Cdc42 expression and activation by targeting RAB22A.Available data indicate that miR-30b-5p plays an anti-gastric cancer role in mediating pPeOp.pPeOp upregulates miR-30b-5p expression,which in turn inhibits RAB22A expression,resulting in a reduction in the expression and activation of Rac1 and Cdc42 and their downstream targets,thus destroying the cytoskeletal structure and inhibiting the proliferation,migration,and invasion of cancer cells. | Wenjun Xu Zhenjie Fu Yuqin Xu Man Hei Cheung Yan Chen Meiai Lin Hang Wen Hang Lv Chun Liang Jianshu Lou Yitao Chen | 2022 | Acta Biochimica et Biophysica Sinica2022，54，12： | 0 |
| 3 | Efficacy of Vaccine Protection Against COVID-19 Virus Infection in Patients with Chronic Liver Diseases显示文摘The outbreak of coronavirus disease 2019 (COVID-19) has resulted in significant morbidity and mortality worldwide. Vaccination against coronavirus disease 2019 is a use-ful weapon to combat the virus. Patients with chronic liver diseases (CLDs), including compensated or decompensated liver cirrhosis and noncirrhotic diseases, have a decreased immunologic response to coronavirus disease 2019 vaccines. At the same time, they have increased mortality if infected. Current data show a reduction in mortality when patients with chronic liver diseases are vaccinated. A suboptimal vac-cine response has been observed in liver transplant recipi-ents, especially those receiving immunosuppressive therapy, so an early booster dose is recommended to achieve a better protective effect. Currently, there are no clinical data com-paring the protective efficacy of different vaccines in patients with chronic liver diseases. Patient preference, availability of the vaccine in the country or area, and adverse effect profiles are factors to consider when choosing a vaccine. There have been reports of immune-mediated hepatitis after coronavi-rus disease 2019 vaccination, and clinicians should be aware of that potential side effect. Most patients who developed hepatitis after vaccination responded well to treatment with prednisolone, but an alternative type of vaccine should be considered for subsequent booster doses. Further prospec-tive studies are required to investigate the duration of immu-nity and protection against different viral variants in patients with chronic liver diseases or liver transplant recipients, as well as the effect of heterologous vaccination. | Carmen Ka Man Cheung Kimmy Wan Tung Law Alvin Wing Hin Law Man Fai Law Rita Ho Sunny Hei Wong | 2023 | Journal of Clinical and Translational Hepatology2023，11，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员